Experimental cancer drug trial halted early
NCT ID NCT04799054
First seen Sep 30, 2025 · Last updated May 12, 2026 · Updated 30 times
Summary
This study tested an experimental drug called TransCon TLR7/8 Agonist, given as an injection into tumors, either alone or with another drug (pembrolizumab). It aimed to find a safe dose and check for side effects in people with advanced solid tumors that had stopped responding to standard treatments. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascendis Investigational Site
Los Angeles, California, 90067, United States
-
Ascendis Investigational Site
Orange, California, 92868, United States
-
Ascendis Investigational Site
Tampa, Florida, 33612, United States
-
Ascendis Investigational Site
Dallas, Texas, 75235, United States
-
Ascendis Investigational Site
Dallas, Texas, 75390, United States
-
Ascendis Investigational Site
Houston, Texas, 77030, United States
-
Ascendis Investigational Site
Bedford Park, 5042, Australia
-
Ascendis Investigational Site
Amsterdam, 1066, Netherlands
-
Ascendis Investigational Site
Rotterdam, 3015 GD, Netherlands
-
Ascendis Investigational Site
Dalseo-gu, 42601, South Korea
-
Ascendis Investigational Site
Seocho-gu, 06591, South Korea
-
Ascendis Investigational Site
Seogu, 49201, South Korea
-
Ascendis Investigational Site
Seogu, 49267, South Korea
-
Ascendis Investigational Site
Seongnam, 13620, South Korea
-
Ascendis Investigational Site
Seoul, 03722, South Korea
-
Ascendis Investigational Site
Seoul, 05505, South Korea
-
Ascendis Investigational Site
Seoul, 06273, South Korea
-
Ascendis Investigational Site
Suwon, 16247, South Korea
-
Ascendis Investigational Site
Suwon, 16499, South Korea
-
Ascendis Investigational Site
Barcelona, 08003, Spain
-
Ascendis Investigational Site
Barcelona, 08028, Spain
-
Ascendis Investigational Site
Barcelona, 08035, Spain
-
Ascendis Investigational Site
Barcelona, 08908, Spain
-
Ascendis Investigational Site
Madrid, 28027, Spain
-
Ascendis Investigational Site
Madrid, 28040, Spain
-
Ascendis Investigational Site
Madrid, 28041, Spain
-
Ascendis Investigational Site
Madrid, 28050, Spain
-
Ascendis Investigational Site
Málaga, 29010, Spain
-
Ascendis Investigational Site
Murcia, 30120, Spain
-
Ascendis Investigational Site
Pamplona, 31008, Spain
-
Ascendis Investigational Site
Seville, 41009, Spain
-
Ascendis Investigational Site
Valencia, 46009, Spain
-
Ascendis Investigational Site
Taichung, 404, Taiwan
-
Ascendis Investigational Site
Taichung, 40705, Taiwan
-
Ascendis Investigational Site
Tainan, 704, Taiwan
-
Ascendis Investigational Site
Taipei, 112, Taiwan
-
Ascendis Pharma Investigational Site
Duarte, California, 91010, United States
-
Ascendis Pharma Investigational Site
San Francisco, California, 94158, United States
-
Ascendis Pharma Investigational Site
Chicago, Illinois, 60637, United States
-
Ascendis Pharma Investigational Site
Iowa City, Iowa, 52242, United States
-
Ascendis Pharma Investigational Site
Louisville, Kentucky, 40202, United States
-
Ascendis Pharma Investigational Site
Canton, Ohio, 44718, United States
-
Ascendis Pharma Investigational Site
Cincinnati, Ohio, 45219, United States
-
Ascendis Pharma Investigational Site
Cleveland, Ohio, 44106, United States
-
Ascendis Pharma Investigational Site
Pittsburgh, Pennsylvania, 15232, United States
-
Ascendis Pharma Investigational Site
Knoxville, Tennessee, 37920, United States
-
Ascendis Pharma Investigational Site
Fairfax, Virginia, 22031, United States
-
Ascendis Pharma Investigational Site
Wollongong, New South Wales, 2500, Australia
-
Ascendis Pharma Investigational Site
Frankston, Victoria, 3199, Australia
Conditions
Explore the condition pages connected to this study.